DeCure for Lissencephaly 9 with complex brainstem malformation
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lissencephaly 9 with complex brainstem malformation — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLissencephaly 9 with complex brainstem malformation maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lissencephaly 9 with complex brainstem malformation is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
microtubule actin crosslinking factor 1 (MACF1) — MACF1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Z6G · 2.654 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Lissencephaly 9 with complex brainstem malformation is a severe cortical malformation within the lissencephaly spectrum, characterised by incomplete neuronal migration and a smooth cerebral surface. The 1985 report describes four additional patients with type II lissencephaly, including one with a previously undescribed abnormality: dilated rough endoplasmic reticulum cisternae containing an unknown osmiophilic secretory product, probably a glycoprotein. No therapeutic intervention is mentioned in any of these abstracts; they are purely descriptive of pathology, genetics, and clinical presentation. The 2014 review notes that identification of the genetic basis of lissencephaly syndromes has improved molecular diagnosis and genetic counselling, but it does not report any treatment or drug trial.
The 2007 chapter on cortical malformations states that these disorders are increasingly recognised as a relatively common cause of refractory epilepsy, mental retardation, and other neurological disorders, but again offers no pharmacological data. The 2007 "Smooth mosaics" paper clarifies that severe phenotypes include marked mental retardation, therapy-refractory epilepsy, and cerebral palsy leading to reduced life expectancy, while milder phenotypes involve less severe epilepsy and mild to moderate intellectual impairment. Most patients with the lissencephaly spectrum harbour mutations in LIS1 or DCX, but no drug, repurposed or otherwise, is tested or recommended in any of these sources.
There is no evidence here for any drug efficacy, response rate, survival benefit, or even a candidate compound. The abstracts contain zero clinical trial data, no sample sizes for treatment groups, and no outcome measures related to therapy. The only concrete numbers are qualitative descriptions of severity; no survival statistics or response rates are given. What is missing is any preclinical or clinical work on pharmacological intervention, a defined patient stratification by genetic subtype, and funding for a trial design that could test a repurposed drug against this specific malformation. Without such data, no claim of efficacy can be made.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1985 · 149 citations
Syndromes with lissencephaly. II: Walker‐Warburg and Cerebro‐Oculo‐Muscular syndromes and a new syndrome with type II lissencephaly
AbstractLissencephaly (smooth brain) is an abnormality of brain development characterized by incomplete neuronal migration and a smooth cerebral surface. At least two distinct pathological types occur, each associated with several recognized syndromes. In this paper, we report on the clinical and pathologic manifestations of four additional patients and classify and delineate three separate disorders with type II lissencephaly. We also report on a previously undescribed abnormality in one of the four patients--dilated rough endoplasmic reticulum cisternae containing an unknown osmiophilic secretory product, probably a glycoprotein.
American Journal of Medical Genetics Part C Seminars in Medical Genetics · 2014 · 111 citations
The genetics of lissencephaly
AbstractLissencephaly is a spectrum of severe brain malformations caused by the failure of migrating neurons to reach optimal positions in the developing cerebral cortex. Several syndromes associated with lissencephaly have been characterized in recent years. Identification of the genetic basis of these disorders has brought fascinating insights into the mechanisms of brain development, as well as benefits to patients through improved molecular diagnosis and genetic counseling. This review explores the clinical presentation, radiological features, histological findings and molecular basis of lissencephaly with the aim of facilitating the selection and interpretation of gene tests in patients with 'smooth brain' phenotypes.
The Genetic Basis of Human Cerebral Cortical Malformations
AbstractMalformations of cortical development occur when the normal process of brain development is disrupted. With the widespread use of high-resolution neuroimaging, brain malformations are increasingly being recognized as a relatively common cause orefractory epilepsy, mental retardation, and other neurological disorders. The molecular and genetic bases of many cortical malformations have been elucidated in recent years, both expanding our understanding of the underlying biological processes in brain development and informing our approach to these disorders in clinical practice. This chapter highlights some of these malformations, including disorders of microcephaly, gray matter hetero-topia, lissencephaly syndromes, and polymicrogyria.
AbstractLissencephaly (LIS) is a diffuse cortical malformation caused by an incomplete neuronal migration disorder in early brain development.1 There is a continuum of structural alterations ranging from complete agyria and thickened cortex to variable extent of agyria or pachygyria, and subcortical band heterotopia (SBH) as the mildest form.2 Severe phenotypes include marked mental retardation, therapy refractory epilepsy, and cerebral palsy leading to reduced life expectancy whereas milder phenotypes encompass less severe epilepsy and mild to moderate intellectual impairment.
A majority of patients with a clinical and neuroradiologic manifestation of the lissencephaly spectrum harbor a mutation either in the LIS1 gene or in the doublecortin ( DCX or XLIS ) gene.3 Classic LIS (type I) is associated with mutations in the LIS1 gene whereas patients with typical SBH are prone to carry mutations in the X-chromosomal DCX …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
